Dr Olga Kondrashova received her PhD on molecular profiling of ovarian cancer from the University of Melbourne in 2016. As part of her PhD project, she was involved in the establishment of the ALLOCATE study, a pilot demonstrating feasibility of genomic profiling patients with recurrent ovarian cancer for allocating patients to targeted therapies.
Following this, Olga commenced postdoctoral studies in Professor Clare Scott’s Laboratory at the Walter and Eliza Hall Institute of Medical Research, on the mechanisms of PARPi sensitivity and resistance in ovarian cancer.
In January 2019, she joined Dr Nicola Waddell’s Medical Genomics Group at QIMR Berghofer to further develop her bioinformatic skills and expertise in cancer genomics. Her research is focused on linking cancer genomics with patient treatment responses and on integrating molecular profiling into daily clinical practice.
2019-current: Research Officer, Medical Genomics Group
2019-current: Adjunct Associate Professor, Queensland University of Technology
2019-current: Honorary Fellow, University of Queensland
2019-current: Honorary Appointment, The Walter and Eliza Hall Institute of Medical Research
2016-2018: Post-doctoral Fellow, The Walter and Eliza Hall Institute of Medical Research
in collaboration with Pamela Pollock (QUT) and Clare Scott (WEHI), I am currently focused on a comprehensive genomic analysis of pre-clinical cancer models, including patient-derived xenografts. We aim to explore tumour heterogeneity and improve treatment responses of endometrial and ovarian cancers, with special focus on PARP inhibitors
in collaboration with Po Inglis (RBWH) and Sunil Lakhani (Pathology QLD), we have established a pilot project for integrating machine learning into clinical research, and subsequently clinical practice, aiming to improve breast cancer patient care. We are conducting molecular profiling of breast cancer cells and tumour microenvironment using advanced machine learning. This will allow for improved prognosis predictions and subtype classifications compared to current clinical standards
as part of her PhD studies, coordinated the optimisation, validation and accreditation of the diagnostic assays used in the study ALLOCATE, designed to implement molecular profiling of ovarian cancer into clinical practice in Victoria. The study enabled molecularly-guided treatments and resulted in immediate clinical management changes for a number of patients
post-doctoral research at WEHI led to the identification of two novel mechanisms of ovarian cancer resistance to PARP inhibitors: secondary mutations in RAD51C/D genes and heterozygous BRCA1 methylation. These findings provide information that will help to better match ovarian cancer patients with the appropriate therapy for their cancer
member of The Australasian Genomic Technologies Association (AGTA)
member of QIMR Berghofer Postdoctoral Committee
co-organiser of QIMR Berghofer Early Career Research Seminar Series
member of Australian Bioinformatics and Computational Biology Society (ABACBS)
member of Australian and New Zealand Gynaecological Oncology Group (ANZGOG)
2016: PhD, Department of Pathology, University of Melbourne
2012: Bachelor of Forensic Science (Honours), Bond University